Healthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know
Eli Lilly is making a significant move into the vaccine market, although it currently has no vaccines available. The company is focusing on developing vaccines that address unmet medical needs, including a shingles vaccine with fewer side effects than the current standard. Additionally, Lilly aims to potentially introduce the first vaccine for the Epstein-Barr Virus, which is linked to various serious health conditions.
- ▪Lilly has no vaccines on the market but historically helped distribute the original polio vaccine.
- ▪The new vaccines are in earlier-stage development and may take time to reach the market.
- ▪Lilly's shingles vaccine aims to improve tolerability compared to GSK's Shingrix vaccine, with fewer reported side effects.
Opening excerpt (first ~120 words) tap to expand
Lilly does not have any vaccines on the market, though it historically helped distribute one of the original polio vaccines. The shots across Lilly's new deals are still in earlier-stage development, so they will likely take time until they reach the market. But what they appear to have in common is that they aim to fill unmet needs, whether that's differentiating from what's already on the market or bringing what could be the first-ever vaccine for certain viruses.For example, Curevo is developing a shot against shingles that Lilly hopes could be as effective as the current standard of care but with fewer side effects.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Top.
Discussion
0 commentsMore from CNBC — Top
